Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

References

• Kymriah-epar-product-information. Available at: https://www.ema.europa.eu/documents/product-information/kymriah-epar-product-information_en.pdf. [ cited 2018 Nov 26]
   Google Scholar
• Yescarta-epar-product-information. [cited: 2018 Nov 26]. Available at: https://www.ema.europa.eu/documents/productinformation/yescarta-epar-product-information_en.pdf
   Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic Leukemia. N Engl J Med. 2018Feb1;378(5):439–448 PMID: 29385370; PMCID: PMC5996391
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al., Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26): 2545–2554.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al., Axicabtageneciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26): 2531–2544.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagenemaraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020Sep19;396(10254):839–852. Epub 2020 Sep 1. PMID: 32888407.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell Lymphoma. N Engl J Med. 2020Apr2;382(14):1331–1342. PMID: 32242358; PMCID: PMC7731441.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr, Shah N, et al. IdecabtageneVicleucel in relapsed and refractory multiple Myeloma. N Engl J Med. 2021Feb25;384(8):705–716. PMID: 33626253.
   PubMed Web of Science ®Google Scholar
• Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtageneautoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Abstract #177. Presented at the 2020 American Society of Hematology Annual Meeting, December 5, 2020.
   Google Scholar
• Wagner J, Wickman E, DeRenzo C, et al. Therapy for solid tumors: bright future or dark reality? Mol Ther. 2020 Nov 4;28(11):2320–2339.
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Orlando D, Boffa I, et al. Choice of co-stimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018Mar15;7(6):e1433518 PMID: 29872565; PMCID: PMC5980417
   PubMed Web of Science ®Google Scholar
• Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020Aug;58:102931. Epub 2020 Jul 30. PMID: 32739874; PMCID: PMC7393540.
   Google Scholar
• Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-Cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020Mar;40:1–8. PMID: 32347759.
   PubMedGoogle Scholar
• Davila ML, Riviere I, Wang X, et al. efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–95. doi: https://doi.org/10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Erratum in: Blood. 2016 Sep 15;128(11):1533. PMID: 24876563; PMCID: PMC4093680
   Google Scholar
• Chen F, Teachey DT, Pequignot E, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods. 2016;434:1–8.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138.
   Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells. Sci Transl Med. 2016;8(355):355ra116.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Lacey SF, Shaw PA, et al. identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. CancerDiscov. 2016;6:664–679.
   Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017 Nov 23;130(21):2295–2306. Epub 2017 Sep 18. PMID: 28924019; PMCID: PMC5701525.
   PubMed Web of Science ®Google Scholar
• Faramand R, Jain M, Staedtke V, et al. Tumor microenvironment composition and severe Cytokine Release Syndrome (CRS) influence toxicity in patients with large B-Cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020Sep15;26(18):4823–4831 Epub 2020 Jul 15. PMID: 32669372; PMCID: PMC7501265
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.
   PubMed Web of Science ®Google Scholar
• Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in cAR T cells. Immunity. 2016Feb16;44(2):380–390 Erratum in: Immunity. 2016 Mar 15;44(3):712.Snyder, Nathaniel [corrected to Snyder, Nathaniel W]; Blair, Ian [corrected to Blair, Ian A]. Erratum in: Immunity. 2016 Mar 15;44(3):712.PMID: 26885860
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009Aug;17(8):1453–1464. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278.PMID: 19384291; PMCID: PMC2805264.
   PubMed Web of Science ®Google Scholar
• Gust J, Ponce R, Liles WC, et al. Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020Dec16;11:577027. PMID: 33391257; PMCID: PMC7772425.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Locke FL, Herrera AF, et al. Use outcomes of an anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy, axicabtageneciloleucel (Axi-Cel), for theTreatment of large B Cell Lymphoma (LBCL) in the United States (US). Blood. 2019;134: 764.
   PubMed Web of Science ®Google Scholar
• Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell therapy for adults with diffuse Large B-Cell Lymphoma (DLBCL): real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) registry. Blood. 2019;134:766.
   Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2018;15:47–62.
   Google Scholar
• Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803–1813.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-Brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017Dec;7(12):1404–1419. Epub 2017 Oct 12. PMID: 29025771; PMCID: PMC5718945.
   PubMed Web of Science ®Google Scholar
• Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020Dec;26(12):1878–1887. Epub 2020 Oct 5. PMID: 33020644.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. CancerDiscov. 2018;8:958–971.
   Google Scholar
• Kansagra AJ, Frey NV, Bar M, et al. Clinical utilization of Chimeric Antigen Receptor T cells (CAR-T) in B-Cell Acute Lymphoblastic Leukemia (ALL): an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019;54:1868–1880.
   PubMed Web of Science ®Google Scholar
• Jain T, Bar M, Kansagra AJ, et al. Use of Chimeric Antigen Receptor T cell therapy in clinical practice for relapsed/refractory aggressive B Cell Non-Hodgkin Lymphoma: an expert panel opinion from the American Society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(12):2305–2321.
   PubMed Web of Science ®Google Scholar
• Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [published correction appears in J Hematol Oncol. 2018;11:81]. J Hematol Oncol. 2018;11(1):35.
   PubMedGoogle Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0. [cited 2018 Jul 20] Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Washington (DC): US Department of Health and Human Services; 14 June 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 2019 Feb 26
   Google Scholar
• Buechner J, Grupp SA, Hiramatsu H, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021Jan26;5(2):593–601 PMID: 33496754; PMCID: PMC7839371
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139–303ra139. https://doi.org/10.1126/scitranslmed.aac5415.
   PubMed Web of Science ®Google Scholar
• Shah BD, Bishop MR, Oluwole OO, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021Apr7; blood.2020009098. Epub ahead of print. PMID: 33827116 1381 11–22
   Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. JULIET investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2019Jan3;380(1):45–56. Epub 2018 Dec 1. PMID: 30501490.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020Nov10;4(21):5414–5424 PMID: 33147337; PMCID: PMC7656920
   PubMed Web of Science ®Google Scholar
• Novartis. Prescribing information (Kymriah). East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017
   Google Scholar
• Grana A, Gut N, Williams K, et al. Safety of AxicabtageneCiloleucel for the treatment of relapsed or refractory large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk. 2020Oct8;S2152–2650. 20 30557-7. doi: https://doi.org/10.1016/j.clml.2020.10.005. Epub ahead of print. PMID: 33132101.
   Google Scholar
• Sesques P, Ferrant E, Safar V, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020Nov;95(11):1324–1333. Epub 2020 Aug 25. PMID: 32744738.
   PubMed Web of Science ®Google Scholar
• Rafaniello C, Ferrajolo C, Gaio M, et al. Tisagenlecleucel in children and young adults: reverse translational research by using real-World safety data. Pharmaceuticals (Basel). 2020Sep21;13(9):258 PMID: 32967272; PMCID: PMC7558916
   Google Scholar
• Gajra A, Zettler ME, Phillips Jr EG Jr, et al. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy. 2020Oct;12(14):1077–1082. Epub 2020 Aug 18. PMID: 32808566.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024–3033.
   PubMed Web of Science ®Google Scholar
• Martino M, Alati C, Canale FA, et al. A review of clinical outcomes of CAR T-Cell therapies for B-Acute lymphoblastic leukemia. Int J Mol Sci. 2021 Feb 21;22(4):2150.
   PubMed Web of Science ®Google Scholar
• Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676–686.
   PubMed Web of Science ®Google Scholar
• Martino M, Canale FA, Alati C, et al. CART-Cell therapy: recent advances and new evidence in multiple Myeloma. Cancers (Basel). 2021 May 27;13(11):2639.
   PubMed Web of Science ®Google Scholar
• Myers GD, Verneris MR, Goy A, et al. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021 Apr;9(4):e002056.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–3330.
   PubMed Web of Science ®Google Scholar
• Yáñez L, Sánchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019Mar29;3(2):e186. PMID: 31723825; PMCID: PMC6746032.
   PubMed Web of Science ®Google Scholar
• Galli E, Allain V, Di Blasi R, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020 Dec;55(12):2347–2349.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–4102.
   PubMed Web of Science ®Google Scholar
• Davila ML, Kloss CC, Gunset G, et al. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 2013;8(4):e61338.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer. 2018;65(4):2017–2018.
   Web of Science ®Google Scholar
• Guiding principles for effective use of IVIG for Patients with Primary Immunodeficiency. [ cited 2018 Jul 27]. Available at: https://www.aaaai.org/Aaaai/media/MediaLibrary/PDFDocuments/PracticeResources/IVIG-guiding-principles.pdf
   Google Scholar
• Ragoonanan D, Khazal SJ, Abdel-Azim H, et al. diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021Feb19; doi: https://doi.org/10.1038/s41571-021-00474-4 Epub ahead of print. Erratum in: Nat Rev Clin Oncol. 2021 Mar 17;: PMID: 33608690.
   Google Scholar
• Locke F, Neelapu SS, Bartlett N, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive Non-Hodgkin Lymphoma (NHL). Blood. 2017;130(Supplement 1):1547.
   Google Scholar
• Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020Jul14;4(13):3123–3127 PMID: 32645136; PMCID: PMC7362369
   PubMed Web of Science ®Google Scholar
• van Nieuwenhuijze A, Koenders M, Roeleveld D, et al. GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol. 2013Dec;56(4):675–682. Epub 2013 Aug 8. PMID: 23933508.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang S, Jiang T, et al. High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. Cell Mol Immunol. 2019 Jun;16(6):602–610. Epub 2018 Oct 16. PMID: 30327490; PMCID: PMC6804788. 16
   PubMed Web of Science ®Google Scholar
• Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019Feb14;133(7):697–709 Epub 2018 Nov 21. PMID: 30463995; PMCID: PMC6376281.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124–e131.
   PubMed Web of Science ®Google Scholar
• Lu P, Lu X-A, Zhang X, et al. Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process. Proc Am Soc Clin Oncol. 2018;36(suppl 15):3041 (abstr).
   Web of Science ®Google Scholar
• DeAngelo D, Ghobadi A, Park J, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET study). J Immunother Cancer. 2017;5(suppl 2):116 (abstr).
   Google Scholar
• Dwivedy Nasta S, Hughes ME, Namoglu EC, et al. A characterization of bridging therapies leading up to commercial CAR T-cell therapy. Blood. 2019;134(suppl 1):4108 (abstr).
   Google Scholar
• Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4.
   PubMedGoogle Scholar
• Maude SL. CAR emissions: cytokines tell the story. Blood. 2017Nov23;130(21):2238–2240. PMID: 29170192.
   PubMed Web of Science ®Google Scholar
• Shah GL, Park J, Sauter CS, et al. Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies [abstract]. Biol Blood Marrow Transplant. 2019;25(3):S38–S39.
   Web of Science ®Google Scholar
• Li H, Zhao Y. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017;8(8):573–589.
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, et al. toxicity and management in CAR T-cell therapy. Mol Ther - Oncolytics. 2016;3:16011.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113–117.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated k light chains. J Clin Invest. 2016;126(7):2588–2596.
   PubMed Web of Science ®Google Scholar
• Kim MY, Yu KR, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018May31;173(6):1439–1453.e19 Epub 2018 May 31. PMID: 29856956; PMCID: PMC6003425.394
   PubMed Web of Science ®Google Scholar